Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04042740
Other study ID # ACTG A5380
Secondary ID 38553UM1AI068636
Status Completed
Phase Phase 2
First received
Last updated
Start date November 15, 2019
Est. completion date August 22, 2023

Study information

Verified date March 2024
Source AIDS Clinical Trials Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks in acute hepatitis C (HCV)-infected participants, with or without HIV-1 coinfection.


Description:

The study will be conducted in two steps. In Step 1, participants will receive four weeks of treatment with G/P for acute HCV infection and then followed 24 weeks post treatment. Participants with HCV recurrence (reinfection, suspected relapse or undefined post-treatment viremia) or HCV virologic failure before or at the Step 1 Week 16/SVR12 (sustained virologic response 12 weeks post-treatment) visit may enter Step 2 for re-treatment. The remaining participants complete the study at Week 28 of Step 1. The study primary and secondary outcome measures pertain to Step 1. In Step 2, participants will be re-treated with G/P with or without ribavirin (RBV) for up to 16 weeks, and followed for 24 weeks post treatment. Post-treatment follow-up for Step 2 will include visits for SVR12 determination after re-treatment. In Step 1, study visits are scheduled at study entry, weeks 1 and 2 (on-treatment), week 4 (treatment discontinuation), and weeks 8, 12, 16 and 28 (post-treatment follow-up). In Step 2, participants will have study visits during the re-treatment period, where the number of visits depends on the re-treatment, and visits at 12 and 24 weeks post treatment. Study visits may include physical examinations, clinical assessments, blood and urine collection, questionnaires, and HCV re-infection prevention counseling.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date August 22, 2023
Est. primary completion date May 18, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Acute HCV infection (or reinfection) within 24 weeks prior to entry. - Detectable HCV RNA at the screening visit. Exclusion Criteria - Any HCV treatment during the current acute HCV infection episode. - Known preexisting cirrhosis - Acute HIV-1 infection - Presence of active or acute AIDS-defining opportunistic infections, active serious infection (other than HIV-1 or HCV), active hepatitis B virus (HBV) or active hepatitis A virus (HAV) - Chronic use of systemically administered immunosuppressive agents - History of solid organ transplantation. - History of conditions that could interfere with the absorption of the study drug. - Concurrent use of prohibited medications - Known hypersensitivity to glecaprevir or pibrentasvir, the metabolites, or parts of the formulation. - Females who are pregnant or breastfeeding - Males with pregnant female partner.

Study Design


Intervention

Drug:
Glecaprevir/Pibrentasvir (G/P)
Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
Ribavirin (RBV)
Tablets containing 200 mg of ribavirin. RBV dosed according to weight-based and renal dosing tables in study protocol.

Locations

Country Name City State
Brazil Instituto de Pesquisa Clinica Evandro Chagas (12101) Rio de Janeiro
United States University of Colorado Hospital CRS (6101) Aurora Colorado
United States Johns Hopkins Adult AIDS CRS Baltimore Maryland
United States Massachusetts General Hospital ACTG CRS (101) Boston Massachusetts
United States Unc Aids Crs (3201) Chapel Hill North Carolina
United States Columbia Physicians and Surgeons CRS (30329) New York New York
United States Weill Cornell Chelsea CRS (7804) New York New York
United States Weill Cornell Upton CRS (7803) New York New York
United States Ucsd, Avrc Crs (701) San Diego California
United States University of California, San Francisco HIV/AIDS CRS (801) San Francisco California
United States University of Washington AIDS CRS (1401) Seattle Washington
United States Whitman-Walker Institute, Inc. CRS (31791) Washington District of Columbia

Sponsors (3)

Lead Sponsor Collaborator
AIDS Clinical Trials Group AbbVie, National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

United States,  Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants with sustained virologic response at 12 weeks post-treatment (SVR12) SVR12 defined as achieving unquantifiable HCV RNA (less than the lower limit of quantification [LLOQ] target detected [TD] or target not detected [TND]) at study visit 12 weeks post treatment. If a participant does not have any HCV RNA measurements in this time period then the participant will be considered as SVR12 failure, unless there are preceding and subsequent HCV RNA measurements that are both LLOQ (either TD or TND). Week 16 (12 weeks post treatment)
Primary Proportion of participants who experienced adverse events (AEs) Study protocol required reporting of (1) AEs Grade greater than or equal to 2, (2) AEs that led to a change in study treatment regardless of grade and (3) AEs meeting ICH definition of SAE or Expedited AE (EAE) reporting requirement. DAIDS AE Grading Table (V2.1) and DAIDS EAE Manual (V2.0) are used. From study treatment initiation to 4 weeks after study treatment discontinuation (Week 8)
Primary Number of participants who complete 4 weeks of treatment without discontinuation due to AEs Number of participants who complete 4 weeks of treatment without discontinuation due to AEs From study entry to Week 4
Secondary Proportion of participants with HCV RNA less than LLOQ Proportion of participants with HCV RNA less than LLOQ (TD or TND) Weeks 1, 2, 4, 8, 12, 28
Secondary Number of participants with HCV virologic failure Virologic failure defined as failure to achieve unquantifiable HCV RNA and confirmed increase in HCV RNA greater than 1 log10 from on-treatment nadir Weeks 1, 2, 4
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02135419 - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Phase 3
Active, not recruiting NCT02663856 - My Smart Age With HIV: Smartphone Self-assessment of Frailty
Completed NCT02921516 - Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings N/A
Completed NCT02846402 - Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda N/A
Completed NCT02663869 - Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
Completed NCT02659306 - Metformin Immunotherapy in HIV Infection Phase 1
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Completed NCT02564341 - Targeting Effective Analgesia in Clinics for HIV - Intervention N/A
Active, not recruiting NCT02302950 - A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas N/A
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Completed NCT01852942 - Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV Phase 2
Completed NCT02269605 - Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment Phase 1
Completed NCT01830595 - Lactoferrin Treatment in HIV Patients Phase 2
Terminated NCT01902186 - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Phase 4
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Completed NCT02525146 - Birmingham Access to Care Study N/A
Completed NCT02527135 - Text Messaging to Improve HIV Testing Among Young Women in Kenya N/A
Completed NCT02118168 - Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002 N/A
Active, not recruiting NCT02602418 - Neural Correlates of Working Memory Training for HIV Patients N/A
Completed NCT01680094 - Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART Phase 1/Phase 2